文献速递胃肠动力与功能性疾病

COVID-19康复后持续的胃肠道表现

Prolonged Gastrointestinal Manifestations After Recovery From COVID-19.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-11-22

在北美住院COVID-19幸存者中随访12-18个月,530例受邀者中116例应答,60.3%符合至少一种罗马IV功能性胃肠病诊断,高于美国一般人群(P<.0001)。初诊时有胃肠道症状者42.1%症状持续,心理创伤评分是随访时胃肠道症状严重度的最强预测因子。

要点

  • COVID-19住院幸存者随访12-18个月,60.3%符合至少一种罗马IV功能性胃肠病诊断,高于美国一般人群(P<.0001)。
  • 住院期间有胃肠道症状者42.1%随访时至少保留一种症状,而任何COVID相关症状保留率为89.8%。
  • 心理创伤评分(事件影响量表修订版≥33)见于41.4%应答者,与功能性胃肠病患病率及胃肠道症状严重度较高相关。

核心结论

  • COVID-19住院后12-18个月随访中,功能性胃肠病和持续性胃肠道症状患病率较高。
  • 持续的胃肠道表现与住院期间胃肠道症状严重度及与该病经历相关的心理创伤程度相关。

研究设计与样本

  • 研究嵌套于一项覆盖北美的COVID-19住院患者大型观察性队列研究。
  • 对530例幸存者在12-18个月后进行随访调查,评估持续性胃肠道症状及其严重度以及功能性胃肠病(DGBIs)的发生。
  • 合格患者在研究中心层面被识别并接受电子调查。
  • 调查工具包括罗马IV功能性胃肠病诊断问卷、24项COVID相关症状评定量表、胃肠道症状评定量表以及事件影响量表修订版创伤症状问卷。
  • 进行回归分析以探索随访时胃肠道症状严重度的相关因素。

主要发现

  • 530例受邀患者中116例应答(女性52.6%;平均年龄55.2岁),其中73例(60.3%)在随访时符合至少一种罗马IV功能性胃肠病诊断,高于美国一般人群患病率(P<.0001)。
  • 住院期间有COVID相关胃肠道症状(腹痛、恶心、呕吐或腹泻)者中,42.1%在随访时至少保留其中一种症状;相比之下,89.8%的应答者保留任何(胃肠道或非胃肠道)COVID相关症状。
  • 自我报告的初始COVID-19期间中度或重度胃肠道症状数量与随访时功能性胃肠病的发生及胃肠道症状严重度相关。
  • 41.4%的应答者存在与COVID-19疾病经历相关的创伤后应激障碍(事件影响量表修订版评分≥33),这些个体的功能性胃肠病患病率和胃肠道症状严重度更高。
  • 回归分析显示,较高的心理创伤评分(事件影响量表修订版)是随访时胃肠道症状严重度的最强预测因子。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Acute enteric infections are well known to result in long-term gastrointestinal (GI) disorders. Although COVID-19 is principally a respiratory illness, it demonstrates significant GI tropism, possibly predisposing to prolonged gut manifestations. We aimed to examine the long-term GI impact of hospitalization with COVID-19. METHODS: Nested within a large-scale observational cohort study of patients hospitalized with COVID-19 across North America, we performed a follow-up survey of 530 survivors 12-18 months later to assess for persistent GI symptoms and their severity, and for the development of disorders of gut-brain interaction (DGBIs). Eligible patients were identified at the study site level and surveyed electronically. The survey instrument included the Rome IV Diagnostic Questionnaire for DGBI, a rating scale of 24 COVID-related symptoms, the Gastrointestinal Symptoms Rating Scale, and the Impact of Events-Revised trauma symptom questionnaire (a measure of posttraumatic stress associated with the illness experience). A regression analysis was performed to explore the factors associated with GI symptom severity at follow-up. RESULTS: Of the 530 invited patients, 116 responded (52.6% females; mean age, 55.2 years), and 73 of those (60.3%) met criteria for 1 or more Rome IV DGBI at follow-up, higher than the prevalence in the US general population (P < .0001). Among patients who experienced COVID-related GI symptoms during the index hospitalization (abdominal pain, nausea, vomiting, or diarrhea), 42.1% retained at least 1 of these symptoms at follow-up; in comparison, 89.8% of respondents retained any (GI or non-GI) COVID-related symptom. The number of moderate or severe GI symptoms experienced during the initial COVID-19 illness by self-report correlated with the development of DGBI and severity of GI symptoms at follow-up. Posttraumatic stress disorder (Impact of Events-Revised score ≥33) related to the COVID-19 illness experience was identified in 41.4% of respondents and those individuals had higher DGBI prevalence and GI symptom severity. Regression analysis revealed that higher psychological trauma score (Impact of Events-Revised) was the strongest predictor of GI symptom severity at follow-up. CONCLUSIONS: In this follow-up survey of patients 12-18 months after hospitalization with COVID-19, there was a high prevalence of DGBIs and persistent GI symptoms. Prolonged GI manifestations were associated with the severity of GI symptoms during hospitalization and with the degree of psychological trauma related to the illness experience.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Elmunzer BJ, Palsson OS, Forbes N, et al. Prolonged Gastrointestinal Manifestations After Recovery From COVID-19. Clin Gastroenterol Hepatol. 2023. PMID: 37995983. doi:10.1016/j.cgh.2023.11.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。